

BAXTER INTERNATIONAL INC.
Key Product Line Sales by U.S. and International
Three-Month Periods Ending June 30, 2010 and 2009
(unaudited)
(\$ in millions)

	Q2 2010			Q2 2009			% Growth		
	U.S.	International	Total	U.S.	International	Total	U.S.	International	Total
BioScience									
Recombinants	\$233	\$292	\$525	\$230	\$285	\$515	1%	2%	2%
Plasma Proteins	110	204	314	118	235	353	(7%)	(13%)	(11%)
Antibody Therapy	211	99	310	255	89	344	(17%)	11%	(10%)
Regenerative Medicine	76	57	133	62	47	109	23%	21%	22%
Other ¹	6	70	76	6	91	97	0%	(23%)	(22%)
Total BioScience	\$636	\$722	\$1,358	\$671	\$747	\$1,418	(5%)	(3%)	(4%)
Medication Delivery									
IV Therapies	\$134	\$284	\$418	\$116	\$268	\$384	16%	6%	9%
Global Injectables	263	209	472	228	190	418	15%	10%	13%
Infusion Systems	132	84	216	122	83	205	8%	1%	5%
Anesthesia	84	46	130	79	41	120	6%	12%	8%
Other	(1)	4	3	1	6	7	N/M	(33%)	(57%)
Total Medication Delivery	\$612	\$627	\$1,239	\$546	\$588	\$1,134	12%	7%	9%
Renal									
PD Therapy	\$79	\$401	\$480	\$76	\$378	\$454	4%	6%	6%
HD Therapy	19	86	105	20	76	96	(5%)	13%	9%
Total Renal	\$98	\$487	\$585	\$96	\$454	\$550	2%	7%	6%
Transfusion Therapies²	\$9	\$3	\$12	\$12	\$9	\$21	(25%)	(67%)	(43%)
Total Baxter	\$1,355	\$1,839	\$3,194	\$1,325	\$1,798	\$3,123	2%	2%	2%

¹ Principally includes vaccines and sales of plasma to third parties.

² Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture.